Literature DB >> 12767524

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.

Yuka Sasakawa1, Yoshinori Naoe, Takeshi Inoue, Tatsuya Sasakawa, Masahiko Matsuo, Toshitaka Manda, Seitaro Mutoh.   

Abstract

In this study, we examined the effects of FK228 (FR901228, depsipeptide) on tumor growth and expression of p21 and c-myc genes in vivo. FK228 induced the expression of p21 mRNA and decreased c-myc mRNA in tumor xenograft sensitive to FK228. However, FK228 did not sufficiently modulate the expression of p21 mRNA and increased the expression of c-myc in tumor xenograft less sensitive to FK228. The modulation of p21 and/or c-myc genes may be critical for the marked antitumor activity of FK228 in vivo.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12767524     DOI： 10.1016/s0304-3835(03)00184-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

2.  Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.

Authors:  Abraham Jacob; Janet Oblinger; Matthew L Bush; Victoria Brendel; Griffin Santarelli; Abhik R Chaudhury; Samuel Kulp; Krista M D La Perle; Ching-Shih Chen; Long-Sheng Chang; D Bradley Welling
Journal:  Laryngoscope       Date:  2011-11-22       Impact factor: 3.325

3.  Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.

Authors:  YanGuo Kong; Gustavo A Barisone; Ranjit S Sidhu; Robert T O'Donnell; Joseph M Tuscano
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

Review 4.  The role of histone deacetylases in prostate cancer.

Authors:  Ata Abbas; Sanjay Gupta
Journal:  Epigenetics       Date:  2008-11-24       Impact factor: 4.528

5.  Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.

Authors:  Syu-Ichi Kanno; Naoyuki Maeda; Ayako Tomizawa; Shin Yomogida; Tadashi Katoh; Masaaki Ishikawa
Journal:  Int J Oncol       Date:  2012-06-06       Impact factor: 5.650

Review 6.  Targeting histone deacetylases for the treatment of disease.

Authors:  M W Lawless; S Norris; K J O'Byrne; S G Gray
Journal:  J Cell Mol Med       Date:  2008-11-03       Impact factor: 5.310

7.  The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

Authors:  Franco Conforti; Elizabeth R Davies; Claire J Calderwood; Thomas H Thatcher; Mark G Jones; David E Smart; Sumeet Mahajan; Aiman Alzetani; Tom Havelock; Toby M Maher; Philip L Molyneaux; Andrew J Thorley; Teresa D Tetley; Jane A Warner; Graham Packham; A Ganesan; Paul J Skipp; Benjamin J Marshall; Luca Richeldi; Patricia J Sime; Katherine M A O'Reilly; Donna E Davies
Journal:  Oncotarget       Date:  2017-07-25

8.  HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter.

Authors:  Chengxiu Hu; Kai Peng; Qianqian Wu; Yiying Wang; Xing Fan; Dai-Min Zhang; Anthony G Passerini; ChongXiu Sun
Journal:  Theranostics       Date:  2021-03-20       Impact factor: 11.556

9.  Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.

Authors:  R Kuefer; M D Hofer; V Altug; C Zorn; F Genze; K Kunzi-Rapp; R E Hautmann; J E Gschwend
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.